Cancer immunotherapy is a next-generation treatment strategy for many different types of cancer. This strategy focuses on the body’s adaptive immune system to recognise and specifically attack cancer cells while leaving healthy cells undamaged. This may offer a safer and more effective treatment option for patients suffering from late-stage cancers or those that have metastasised, or patients for whom conventional treatments have proven ineffective.
CAR T-Cells are generated from a patient’s own T-Cells and are engineered in a specialised cell laboratory to express antibody-like chimeric antigen receptors for targeting specific cancer cells via surface or intracellular proteins. MGRC’s CAR T-Cell immunotherapy is available to patients across Southeast Asia on a compassionate use basis.